EBSEmergent BioSolutions Inc.

NYSE emergentbiosolutions.com


$ 7.61 $ 0.26 (3.61 %)    

Wednesday, 04-Sep-2024 11:22:11 EDT
QQQ $ 462.80 $ 3.71 (0.81 %)
DIA $ 411.55 $ 1.61 (0.39 %)
SPY $ 552.81 $ 2.76 (0.49 %)
TLT $ 98.35 $ 0.47 (0.48 %)
GLD $ 230.59 $ 0.77 (0.34 %)
$ 7.39
$ 7.34
$ 7.15 x 2,500
$ 10.20 x 100
$ 7.11 - $ 7.66
$ 1.42 - $ 15.10
3,745,838
na
390.98M
$ 1.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-01-2024 03-31-2024 10-Q
3 03-08-2024 12-31-2023 10-K
4 12-11-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-01-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-01-2022 06-30-2022 10-Q
10 04-28-2022 03-31-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 11-05-2021 09-30-2021 10-Q
13 07-30-2021 06-30-2021 10-Q
14 04-30-2021 03-31-2021 10-Q
15 02-19-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 07-31-2020 06-30-2020 10-Q
18 05-01-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-02-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-22-2019 12-31-2018 10-K
24 11-02-2018 09-30-2018 10-Q
25 08-03-2018 06-30-2018 10-Q
26 05-04-2018 03-31-2018 10-Q
27 02-23-2018 12-31-2017 10-K
28 11-03-2017 09-30-2017 10-Q
29 08-04-2017 06-30-2017 10-Q
30 05-05-2017 03-31-2017 10-Q
31 02-28-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 03-06-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 emergent-biosolutions-closed-a-new-credit-facility-agreement-with-oak-hill-advisors-for-a-term-loan-of-up-to-250m-and-repaid-senior-term-loan-facility-dated-october-15-2018-which-was-scheduled-to-mature-in-may-2025

The New Term Loan maturity extends up to five years, through August 2029. Excess proceeds from the refinancing will result in a...

 mpox-vaccine-emergent-biosolutions-smallpox-vaccine-gets-fda-nod-for-expanded-use-for-individuals-at-high-risk-of-mpox-infection

The FDA has approved Emergent BioSolutions' supplemental Biologics License Application for ACAM2000 to include the preventi...

 reported-earlier-emergent-biosolutions-acam2000-vaccine-gains-fda-nod-for-mpox-indication-amidst-rising-public-health-crisis

Emergent BioSolutions announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics Licens...

Core News & Articles

- Reuters

Core News & Articles

https://www.reviewjournal.com/life/health/mpox-case-reported-at-clark-county-detention-center-3148320/ One case of mpox has bee...

 who-seeks-135m-in-funding-to-fight-mpox-outbreak-can-be-controlled-and-can-be-stopped

To fight the mpox outbreak in Africa, the World Health Organization calls for funding help for its six-month plan.

Core News & Articles

https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-member-states-information-sessio...

 rodman--renshaw-initiates-coverage-on-emergent-biosolutions-with-buy-rating-announces-price-target-of-16

Rodman & Renshaw initiates coverage on Emergent BioSolutions (NYSE:EBS) with a Buy rating and announces Price Target of $16.

Core News & Articles

https://www.fox2detroit.com/news/mpox-wayne-county-health-department-confirms-first-case-since-2022?taid=66c643be103e400001efc3...

Core News & Articles

- Reuters 

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION